600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions
Status:
Completed
Trial end date:
2002-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the bioequivalence between Amoxicillin and
Clavulanate Potassium for Oral Suspension, 600/42.9 mg/5 mL and Augmentin ES-600™ for Oral
Suspension, 600/42.9 mg/5 mL in healthy, male and female subjects, under fasting conditions.